Comparative outcome analysis of hydroxychloroquine/chloroquine, remdesivir and standard of care treatment against COVID-19 infection

Autor:	Sumit Kumar Mahato, Vikas Kumar
Rok vydání:	2020
Předmět:	medicine.medical_specialty Standard of care Coronavirus disease 2019 (COVID-19) Chloroquine business.industry Internal medicine medicine Outcome analysis Hydroxychloroquine business medicine.drug
Zdroj:	International Journal of Basic & Clinical Pharmacology. 10:122
ISSN:	2279-0780 2319-2003
DOI:	10.18203/2319-2003.ijbcp20205550
Popis:	This study aimed to compare the efficacy and safety of hydroxychloroquine/chloroquine (HCQ/CQ), remdesivir and standard of care treatment (SOC) in patients with nCoV-19 based on the RCTs available in the literature. We conducted a cumulative review of all the RCTs published for the treatment of nCoV-19. Analysis for odds of patient recovery on HCQ/CQ, remdesivir and SOC treatment was accomplished and recovery was expressed as undetectable viral RNA levels. Total sample size in our analysis was 978 from six RCTs, in which nCoV-19 positive patients treated with HCQ/CQ, remdesivir and SOC were 166,560 and 252, respectively. SOC treatment showed increase in 2-fold of patients’ recovery as compared to the HCQ/CQ group (p=0.0006). Further, patients reported 1.5-3-fold increase in adverse events in remdesivir and HCQ/CQ group as compared to SOC group (p=0.0016 and p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8708a3ea2bdedf22bad15319e9e2e639 https://doi.org/10.18203/2319-2003.ijbcp20205550 Zobrazit plný text záznamu